Group items matching

in title, tags, annotations or url

Pfizer said on Thursday (June 1) data from late-stage trials showed its experimental combination of antibiotics was effective in treating deadly infections caused by drug-resistant bacteria. Deaths from antibiotic-resistant bacteria, also known as superbugs, have been on the rise globally, and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and existing generic drug metronidazole with a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and types of hospital-acquired pneumonia. Hospital-acquired pneumonia occurs in patients at least two to three days after being admitted, or in those who have life-threatening lung infections with high mortality rates and who are on mechanical breathing machines. Pfizer said the data from the studies shows the antibiotic combination of ATM-AVI is effective and well-tolerated in treating infections caused by gram-negative bacteria. The cure rate in patients with complicated intra-abdominal infections with Pfizer's combination therapy, along with existing generic drug metronidazole, was 76.4%, versus 74% using the other antibiotics.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

In its response to a Freedom of Information Request (FOI), the NHS Business Services Authority (NHSBSA) has confirmed a net decrease of 101 pharmacies in England - with 371 closures and 270 new contracts. Meanwhile, the General Pharmaceutical Council data projected a drop of 43 registered pharmacies in England, Wales, and Scotland for the year ending March 31, 2023, compared to the preceding period. The data, released by business advisor Christie & Co in its annual pharmacy market review on Sept. 5, revealed a total of 14,328 pharmacies across all four UK country regions as of March 31, 2023, indicating a 0.3 per cent decrease from the previous year. Corporate operators experienced a net reduction of 249 pharmacies, while the total number of independent operators remained consistent with 2022. According to the study, the corporate sector saw the most substantial shift, with a 13.7 per cent reduction in businesses operating 300 or more pharmacies. Following closely, groups managing 11 to 15 pharmacies experienced a 5.6 per cent decrease. Christie & Co attributed this shift in group size to operators acquiring additional pharmacies through corporate disposal opportunities throughout the year.

NHS England delivered 358 million general practice (GP) appointments, including Covid-19 vaccinations, in the 12 months to October 2023, an increase of 50.9 million compared to October 2019. This equals to 44 more appointments per practice per working day, with over 70 per cent of these taking place within two weeks of booking, data published by NHSE on Thursday (30 November) showed. Health Minister, Andrea Leadsom, thanked GPs and primary care teams across the country for making it possible to deliver around 32,500 more appointments every day, which clearly demonstrate that "more people are getting the care they need, when they need it." "While this is positive news, we know that there is more to do to make it easier and quicker for patients to contact their general practice and continue to focus on delivering the Primary Care Recovery Plan," she added. The Primary Care Recovery Plan published earlier this year is focused on improving access to primary care. It provided GPs in England with £240 million to support them to embrace the latest technology to tackle the 8am rush, and handle more appointments. As of August 2023, more than 1,000 general practices had signed up to digital upgrades to make booking GP appointments easier.

Britain has started counting possible Covid-19 reinfections in its daily coronavirus data, changing its approach to reflect the increased number of people catching the disease for a second time as the Omicron variant predominates. The UK Health Security Agency (UKHSA) added around 840,000 cases to the cumulative total, taking it to 17.3 million coronavirus infections reported. Britain's daily Covid statistics previously would only count people who had tested positive for the first time to avoid double-counting people who had received multiple positive test results for the same infection. However, with variants such as Omicron leading to an increase in reinfections, the UKHSA said it would change its method to treat positive tests as separate infections if there was at least 90 days between test results. The change took effect on Monday (January 31). "Reinfection remained at very low levels until the start of the Omicron wave. It is right that our daily reporting processes reflect how the virus has changed," said Steven Riley, UKHSA's Director General of data and Analytics.

Deaths caused by hepatitis C has declined by 35 per cent in England between 2015 and 2020, latest data from the UK Health Security Agency (UKHSA) revealed. It showed that estimated prevalence of chronic hepatitis C in England has continued to fall to around 81,000 in 2020 from 129,000 in 2015, showing a considerable progress has been made towards eliminating the virus as a public health problem by 2030 in England. Commenting on the data release, health and social care secretary Sajid Javid, said: "It is fantastic to see the significant progress that has been made in eliminating hepatitis C in England. Deaths and prevalence of the virus have fallen consistently thanks to improvements in diagnosis, access to treatments and the hard work of the NHS. "This is another example of the UK being at the forefront of tackling serious diseases. We are on track to eliminate this virus by 2030 and I urge anyone who may be at risk to get tested as soon as possible."

The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare professional.' The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022. In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data and asked for advice from the independent Commission on Human Medicines (CHM). "The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no other effective or tolerated treatment," said MHRA. "Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective or tolerated treatment or the risks do not apply."

New data published by NHS England on Thursday (4 January) showed that more than 31.4 million GP appointments (excluding vaccinations) were delivered in November 2023. This is four million more than the number recorded in the same month before the pandemic, and is considered the busiest November on record for GP teams. Compared to the previous month (October 2023), 3.3 per cent more appointments were booked and attended on the same day in November. Almost seven in ten patients attended their appointments within seven days of booking, an increase of 4.5 per cent from the previous month.

QuickBooks Database Server Manager allows users to make the company's file in the host computer. It comes with multi-user accessibility. If someone wants to use multiple versions of QuickBooks Desktop then they have to install the QuickBooks Database server manager.

QuickBooks Database Server Manager allows users to make the company's file in the host computer. It comes with multi-user accessibility. If someone wants to use multiple versions of QuickBooks Desktop then they have to install the QuickBooks Database server manager.For businesses utilizing QuickBooks with multiple users and shared company files, managing the underlying Database becomes crucial. Here's where the QuickBooks Database Server Manager (DBSM) emerges as a maestro, empowering you to optimize performance, ensure Data security, and streamline collaboration within your financial ecosystem. Let's explore the DBSM's functionalities and unveil its potential to elevate your QuickBooks experience. Benefits of Utilizing the DBSM: By wielding the DBSM, you can reap several advantages: Enhanced Performance: Improved Database management translates to faster Data access, smoother operations, and a more responsive QuickBooks experience for all users. Streamlined Collaboration: Efficient user management and company file organization foster seamless collaboration and Data sharing within your team. Robust Security: The DBSM empowers you to implement robust security measures, safeguarding your sensitive financial Data from unauthorized access or breaches. Reduced Downtime: Proactive monitoring and optimization help prevent performance issues and minimize downtime, ensuring uninterrupted financial operations. Scalability and Cost-Effectiveness: The DBSM caters to growing businesses by efficiently managing multiple users and company files, potentially reducing the need for costly hardware upgrades.

By using the QuickBooks Conversion Tool you can easily import the data from the new QuickBooks file. This tool does not breach the data security. It uses the feature to import files of your own choice. You can easily download it from the website for free.

By using the QuickBooks Conversion Tool you can easily import the data from the new QuickBooks file. This tool does not breach the data security. It uses the feature to import files of your own choice. You can easily download it from the website for free.

Quickbooks File Doctor was built by Intuit, in the year 2012. It is developed to fix problems like company files and networking. It is made with a combination of company diagnostic tools and network diagnostic tools. The File repairing tool is not available for all countries.

Quickbooks File Doctor was built by Intuit, in the year 2012. It is developed to fix problems like company files and networking. It is made with a combination of company diagnostic tools and network diagnostic tools. The File repairing tool is not available for all countries. An About QuickBooks File Doctor is an invaluable tool in any QuickBooks user's arsenal. By understanding its capabilities and following the outlined steps, you can leverage its power to diagnose and potentially repair corrupted or inaccessible company files, ensuring the smooth flow of your financial data and minimizing the risk of data loss. Remember, prevention is key to regular backups and utilizing the File Doctor proactively can go a long way in safeguarding your financial information. Benefits of Using the Tool: By utilizing the File Doctor, you can: Recover Corrupted Files: The tool attempts to repair damaged files, potentially saving you from losing valuable data. Diagnose Network Issues: It identifies network-related problems that prevent accessing shared company files, facilitating troubleshooting. Preventative Maintenance: By regularly running the doctor, you can catch potential issues early on, minimizing the risk of data loss and downtime. Peace of Mind: Knowing you have a tool to potentially revive your files in case of trouble provides valuable peace of mind.

QuickBooks Database Server Manager allows users to make the network Data file of the company in the host computer. It is multi-user accessible. You have to install the QBDSM If you wish to use multiple versions of QuickBooks Desktop. You can't run without installing.

QuickBooks Database Server Manager allows users to make the network Data file of the company in the host computer. It is multi-user accessible. You have to install the QBDSM If you wish to use multiple versions of QuickBooks Desktop. You can't run without installing. An About QuickBooks Database Server Manager (DBSM), a powerful tool facilitating shared access and centralized management of company files on a network. Let's explore its functionalities and delve into how it empowers businesses to navigate the complexities of multi-user environments. Benefits of Implementing the DBSM: By leveraging the DBSM, businesses can reap several advantages: Improved Collaboration: Multiple users can access and work on the company file simultaneously, boosting productivity and efficiency. Enhanced Data Security: Centralized file storage and user permission management strengthen Data security and control. Reduced Downtime: The DBSM minimizes file corruption risks and facilitates faster troubleshooting, minimizing downtime. Scalability: It accommodates growing teams and additional users, adapting to your business needs. Simplified Management: The DBMS provides a centralized platform for managing user access and monitoring network activity.

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8 per cent through season two, compared with efficacy of 88.9 per cent after the first RSV season, which led to the shot's US approval. The data is from a late-stage trial of more than 37,000 participants being conducted in both the Northern and Southern hemispheres. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5 per cent, Pfizer said. The data is similar to the efficacy of GSK's rival RSV shot Arexvy over two seasons, which was released in June.

When calorie data on sugary drinks is displayed in convenience stores, teenagers buy fewer of them, especially African-Americans and children from lower-income neighborhoods, researchers from Johns Hopkins Bloomberg School of Public Health reported in the American Journal of Public Health.

EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.

Seven new 'data hubs' are set to revolutionise medical research across Britain, making the medical histories of millions of NHS patients available to doctors, scientists and academics.